as 12-20-2024 3:38pm EST
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Founded: | 2010 | Country: | United States |
Employees: | N/A | City: | LA JOLLA |
Market Cap: | 218.9M | IPO Year: | 2020 |
Target Price: | N/A | AVG Volume (30 days): | 81.4K |
Analyst Decision: | Hold | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 119.38 | EPS Growth: | N/A |
52 Week Low/High: | $10.80 - $18.95 | Next Earning Date: | 11-14-2024 |
Revenue: | $1,568,000 | Revenue Growth: | 19.24% |
Revenue Growth (this year): | -93.76% | Revenue Growth (next year): | N/A |
INBX Breaking Stock News: Dive into INBX Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Simply Wall St.
a month ago
PR Newswire
a month ago
PR Newswire
2 months ago
Argus Research
2 months ago
MT Newswires
3 months ago
GuruFocus.com
3 months ago
MT Newswires
4 months ago
The information presented on this page, "INBX Inhibrx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.